Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical pharmacokinetics of atomoxetine.
Sauer JM, Ring BJ, Witcher JW. Sauer JM, et al. Among authors: ring bj. Clin Pharmacokinet. 2005;44(6):571-90. doi: 10.2165/00003088-200544060-00002. Clin Pharmacokinet. 2005. PMID: 15910008 Review.
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP. Lobo ED, et al. Clin Pharmacokinet. 2008;47(3):191-202. doi: 10.2165/00003088-200847030-00005. Clin Pharmacokinet. 2008. PMID: 18307373 Clinical Trial.
Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW. Sauer JM, et al. J Pharmacol Exp Ther. 2004 Feb;308(2):410-8. doi: 10.1124/jpet.103.058727. Epub 2003 Nov 10. J Pharmacol Exp Ther. 2004. PMID: 14610241
Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Ring BJ, et al. Drug Metab Dispos. 2002 Mar;30(3):319-23. doi: 10.1124/dmd.30.3.319. Drug Metab Dispos. 2002. PMID: 11854152
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. Ring BJ, et al. J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3. J Pharm Sci. 2011. PMID: 21541938
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG. Lamba V, et al. J Pharmacol Exp Ther. 2003 Dec;307(3):906-22. doi: 10.1124/jpet.103.054866. Epub 2003 Oct 9. J Pharmacol Exp Ther. 2003. PMID: 14551287
Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, Barbuch RJ, Chaudhary A, Ayan-Oshodi MA, Ring BJ. Yi P, et al. Among authors: ring bj. Drug Metab Dispos. 2010 Apr;38(4):554-65. doi: 10.1124/dmd.109.030841. Epub 2010 Jan 14. Drug Metab Dispos. 2010. PMID: 20075192
Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.
Mohutsky MA, Chien JY, Ring BJ, Wrighton SA. Mohutsky MA, et al. Among authors: ring bj. Pharm Res. 2006 Apr;23(4):654-62. doi: 10.1007/s11095-006-9663-4. Epub 2006 Mar 24. Pharm Res. 2006. PMID: 16550474
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. Rehmel JL, et al. Among authors: ring bj. Drug Metab Dispos. 2006 Apr;34(4):600-7. doi: 10.1124/dmd.105.007989. Epub 2006 Jan 13. Drug Metab Dispos. 2006. PMID: 16415119
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. Ring BJ, et al. Clin Pharmacol Ther. 2005 Jan;77(1):63-75. doi: 10.1016/j.clpt.2004.09.006. Clin Pharmacol Ther. 2005. PMID: 15637532 Clinical Trial.
56 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback